Wave Life Sciences
Company Type: Therapeutics
Main focus: Antisense oligonucleotides, RNAi and RNA editing
Company stage: IPO ( WVE)
Diseases: Duchenne muscular dystrophy
Genome-editing tool: GalNAc-conjugated RNA-editing oligonucleotide
Funding stage: I
Location: Cambridge, MA, USA
Website: https://wavelifesciences.com/
Pipeline: https://wavelifesciences.com/pipeline/
Partners: GSK; Takeda
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aims develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimisation, and production of stereopure oligonucleotides.